1-octanol has been researched along with Benign Essential Tremor in 4 studies
1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
octan-1-ol : An octanol carrying the hydroxy group at position 1.
Excerpt | Relevance | Reference |
---|---|---|
"1-Octanol (an 8-C alcohol currently used as a food-flavoring agent) is known to inhibit tremor in essential tremor (ET) animal models at a much lower dose than ethyl alcohol." | 9.11 | Pilot trial of 1-octanol in essential tremor. ( Burstein, AH; Bushara, KO; Goldstein, SR; Grimes, GJ; Hallett, M, 2004) |
"Twenty-one single oral doses of 1-octanol were given to patients with essential tremor (ET) in an open-label dose-escalation study." | 9.11 | Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. ( Bushara, KO; Hallett, M; Mari, Z; Reich, M; Shill, HA, 2004) |
" The half-life of OA was 87." | 6.76 | An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. ( Bowen, D; Buchwald, P; Dong, C; Grimes, GJ; Hallett, M; Haubenberger, D; Ippolito, D; Kalowitz, D; Nahab, FB; Potti, G; Starling, J; Toro, C; Wittevrongel, L, 2011) |
"1-Octanol (an 8-C alcohol currently used as a food-flavoring agent) is known to inhibit tremor in essential tremor (ET) animal models at a much lower dose than ethyl alcohol." | 5.11 | Pilot trial of 1-octanol in essential tremor. ( Burstein, AH; Bushara, KO; Goldstein, SR; Grimes, GJ; Hallett, M, 2004) |
"Twenty-one single oral doses of 1-octanol were given to patients with essential tremor (ET) in an open-label dose-escalation study." | 5.11 | Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. ( Bushara, KO; Hallett, M; Mari, Z; Reich, M; Shill, HA, 2004) |
" The half-life of OA was 87." | 2.76 | An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. ( Bowen, D; Buchwald, P; Dong, C; Grimes, GJ; Hallett, M; Haubenberger, D; Ippolito, D; Kalowitz, D; Nahab, FB; Potti, G; Starling, J; Toro, C; Wittevrongel, L, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nahab, FB | 1 |
Wittevrongel, L | 1 |
Ippolito, D | 1 |
Toro, C | 1 |
Grimes, GJ | 2 |
Starling, J | 1 |
Potti, G | 1 |
Haubenberger, D | 1 |
Bowen, D | 1 |
Buchwald, P | 1 |
Dong, C | 1 |
Kalowitz, D | 1 |
Hallett, M | 3 |
Bushara, KO | 2 |
Goldstein, SR | 1 |
Burstein, AH | 1 |
Shill, HA | 1 |
Mari, Z | 1 |
Reich, M | 1 |
Martin, FC | 1 |
Handforth, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor[NCT00102596] | Phase 2 | 21 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Effects of Octanoic Acid for Treatment of Essential Voice Tremor[NCT01864525] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Octanoic Acid is a metabolite of 1-octanol. Blood plasma levels of octanoic acid were measured at 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose. (NCT00102596)
Timeframe: 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose
Intervention | ng/ml (Mean) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Plasma Octanoic Acid Level at 5 min post-dose | Plasma Octanoic Acid Level at 20 min post-dose | Plasma Octanoic Acid Level at 45 min post-dose | Plasma Octanoic Acid Level at 70 min post-dose | Plasma Octanoic Acid Level at 100 min post-dose | Plasma Octanoic Acid Level at 130 min post-dose | Plasma Octanoic Acid Level at 160 min post-dose | Plasma Octanoic Acid Level at 210 min post-dose | Plasma Octanoic Acid Level at 270 min post-dose | Plasma Octanoic Acid Level at 360 min post-dose | |
64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation | 62.94 | 5064.12 | 7967.97 | 6788.58 | 5701.60 | 5448.23 | 4662.88 | 3179.10 | 2248.74 | 1266.37 |
64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation | 74.16 | 3885.52 | 9645.55 | 13315.26 | 9289.39 | 9605.68 | 6678.69 | 4307.74 | 2618.25 | 872.51 |
(NCT00102596)
Timeframe: 0 minutes, 15 minutes, 100 minutes and 24 hours post-dose
Intervention | beats per minute (Least Squares Mean) | |||
---|---|---|---|---|
Heart Rate at 0 min | Heart Rate at 15 min | Heart Rate at 100 min | Heart Rate at 24 hours | |
1-Octanol Dose | 70.8 | 66.6 | 67.1 | 72.4 |
Spirography mean tremor amplitudes were measured in the right hand of each participant at 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose. Then, the scores of each participant were normalized (i.e., divided by) by their baseline tremor severity scores so that all scores are expressed as a proportion of the baseline score. Therefore, 1 is the baseline tremor severity, and lower scores indicate tremor reduction. (NCT00102596)
Timeframe: 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose
Intervention | normalized score on a scale (Mean) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Normalized score at 0 minutes | Normalized score at 15 minutes post-dose | Normalized score at 30 minutes post-dose | Normalized score at 60 minutes post-dose | Normalized score at 90 minutes post-dose | Normalized score at 120 minutes post-dose | Normalized score at 150 minutes post-dose | Normalized score at 180 minutes post-dose | Normalized score at 240 minutes post-dose | Normalized score at 360 minutes post-dose | |
64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation | 1 | 1.009 | 0.826 | 0.786 | 0.670 | 0.662 | 0.680 | 0.645 | 0.791 | 0.894 |
64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation | 1 | 0.901 | 0.738 | 0.766 | 0.685 | 0.709 | 0.746 | 0.707 | 0.683 | 0.122 |
(NCT00102596)
Timeframe: 0 minutes, 15 minutes, 100 minutes and 24 hours post-dose
Intervention | ms (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
PR Interval at 0 min | PR Interval at 15 min | PR Interval at 100 min | PR Interval at 24 hours | QTc Interval at 0 min | QTc Interval at 15 min | QTc Interval at 100 min | QTc Interval at 24 hours | |
1-Octanol Dose | 168.8 | 172.8 | 171.6 | 168.6 | 433.8 | 436.5 | 433.0 | 437.4 |
Three experienced listeners independently rated each participant's voice from paired sample recordings comparing the baseline to post-test samples in randomized order for each condition. Sustained vowel and sentence-level recordings were rated, with decoded samples later analyzed for 1=better for post-test compared to baseline, 0= no difference between post-test and baseline. Maximum score for each participant was 3 (post-test was better for each of three raters). The range of possible scores was the sum of each of three raters' scores (0 to 3), with 0 indicating no difference between baseline and post-test voice tremor severity rating, and 3 indicating better voice (less tremor severity) at post-testing compared to pre-testing. Mean post-test values for task were compared for the octanoic acid and placebo conditions, and all raters were blind to which sample was a baseline versus a post-test recording, and which samples were associated with the [placebo or octanoic acid conditions. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2).
Intervention | units on a scale (Mean) | |
---|---|---|
Sustained vowel, summed binary ratings (0-3) | Sentence-level, summed binary ratings (0-3) | |
Octanoic Acid | 1.53 | 1.19 |
Placebo | 1.25 | 1.63 |
Voice recordings were used to measure the degree of tremor in the voice. Mean post-test values for each acoustic measure were compared after the octanoic acid and placebo conditions, with and without consideration of baseline values. Mean values represent the average of two testing days. Degree of amplitude tremor shows the extent of amplitude variation as a percent of the mean signal amplitude, with lower numbers indicating less amplitude tremor. Baseline values for magnitude of amplitude tremor across all participants and conditions ranged from 4.06 to 27.09, and post-test values ranged from 1.94 to 26.02. Degree of frequency tremor shows the extent of fundamental frequency variation as a percent of the mean signal frequency, with lower numbers indicating less frequency tremor. Baseline values for magnitude of frequency tremor across all participants and conditions ranged from 1.21 to 15.31, and post-test values ranged from 0.60 to 13.86. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2)
Intervention | percentage of voice signal with tremor (Mean) | |||
---|---|---|---|---|
Baseline Magnitude of Acoustic Amplitude Tremor | Post-test Magnitude of Acoustic Amplitude Tremor | Baseline Magnitude of Acoustic Frequency Tremor | Post-test Magnitude of Acoustic Frequency Tremor | |
Octanoic Acid | 13.49 | 9.35 | 5.19 | 3.98 |
Placebo | 12.91 | 12.43 | 5.57 | 5.35 |
3 trials available for 1-octanol and Benign Essential Tremor
Article | Year |
---|---|
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do | 2011 |
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do | 2011 |
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do | 2011 |
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do | 2011 |
Pilot trial of 1-octanol in essential tremor.
Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male; | 2004 |
Pilot trial of 1-octanol in essential tremor.
Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male; | 2004 |
Pilot trial of 1-octanol in essential tremor.
Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male; | 2004 |
Pilot trial of 1-octanol in essential tremor.
Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male; | 2004 |
Open-label dose-escalation study of oral 1-octanol in patients with essential tremor.
Topics: 1-Octanol; Adult; Aged; Aged, 80 and over; Drugs, Investigational; Essential Tremor; Humans; Middle | 2004 |
1 other study available for 1-octanol and Benign Essential Tremor
Article | Year |
---|---|
Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.
Topics: 1-Octanol; Animals; Carbenoxolone; Central Nervous System Stimulants; Cerebellum; Chloroquine; Conne | 2006 |